Endocrine disruptor actions through receptor crosstalk

• Autorzy: Kiyama R.

Identyfikatory

DOI

10.14799/ebms262

• Języki publikacji: EN

Abstrakty

EN

Endocrine disruptors interfere with hormonal action through receptors and signaling pathways, but receptor crosstalk involved in the actions of endocrine disruptors has not yet been well documented. This review summarizes what is known about the actions of endocrine disruptors through receptor crosstalk, focusing on three model cases: crosstalk involving the estrogen receptor, the androgen receptor, and the thyroid hormone receptor. Here, crosstalk is categorized as bidirectional or unidirectional, with the latter category further subdivided into ligand-dependent or -independent crosstalk. More research needs to be done to develop a clearer understanding of the involvement of receptor crosstalk in cell signaling that is induced by endocrine disruptors. This understanding will help to develop in vitro and in silico assays that can replace animal tests.

Słowa kluczowe

EN

endocrine disruptor; pathway analysis; receptor crosstalk; risk assessment; signal transduction

PL

biomimetyk hormonalny; analiza ryzyka; transdukcja sygnału

• Wydawca: University of Warmia and Mazury in Olsztyn, Poland
• Czasopismo: Environmental Biotechnology
• Rocznik: 2016
• Tom: Vol. 12, No. 1
• Strony: 1--16
• Opis fizyczny: Bibliogr. 189 poz., tab.

Twórcy

autor

Kiyama R.

• Biomedical Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, Ibaraki 305-8566, Japan; Phone: [phone]

Bibliografia

• Ankley, G.T., R.S. Bennett, R.J. Erickson, D.J. Hoff, M.W. Hornung, R.D. Johnson, D.R. Mount, J.W. Nichols, C.L. Russom, P.K. Schmieder, J.A. Serrrano, J.E. Tietge, D.L. Villeneuve. 2010. Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment. Environmental Toxicology and Chemistry 29(3): 730-741.
• Arpino, G., L. Wiechmann, C.K. Osborne, R. Schiff. 2008. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocrine Reviews 29(2): 217-233.
• Band, A.M., M. Laiho. 2011. Crosstalk of TGF-β and estrogen receptor signaling in breast cancer. Journal of Mammary Gland Biology and Neoplasia 16(2): 109-115.
• Barton, M. 2012. Position paper: The membrane estrogen receptor GPER-Clues and questions. Steroids 77(10): 935-942.
• Basualto-Alarcón, C., G. Jorquera, F. Altamirano, E. Jaimovich, M. Estrada. 2013. Testosterone signals through mTOR and androgen receptor to induce muscle hypertrophy. Medicine and Science in Sports and Exercise 45(9): 1712-1720.
• Becker, M.A., Y.H. Ibrahim, X. Cui, A.V. Lee, D. Yee. 2011. The IGF pathway regulates ERα through a S6K1-dependent mechanism in breast cancer cells. Molecular Endocrinology 25(3): 516-528.
• Beildeck, M.E., E.P. Gelmann, S.W. Byers. 2010. Cross-regulation of signaling pathways: an example of nuclear hormone receptors and the canonical Wnt pathway. Experimental Cell Research 316(11): 1763-1772.
• Bender, L.M., R. Nahta. 2008. Her2 cross talk and therapeutic resistance in breast cancer. Frontiers in Bioscience 13: 3906-3912.
• Benmouloud, A., Z. Amirat, F. Khammar, A.V. Patchev, J.M. Exbrayat, O.F. Almeida. 2014. Androgen receptor-mediated regulation of adrenocortical activity in the sand rat, Psammomys obesus. Journal of Comparative Physiology B 184(8): 1055-1063.
• Bonaccorsi, L., D. Nosi, F. Quercioli, L. Formigli, S. Zecchi, M. Maggi, G. Forti, E. Baldi. 2008. Prostate cancer: a model of integration of genomic and non-genomic effects of the androgen receptor in cell lines model. Steroids 73(910): 1030-1037.
• Bostner, J., E. Karlsson, M.J. Pandiyan, H. Westman, L. Skoog, T. Fornander, B. Nordenskjöld, O. Stˆl. 2013. Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit. Breast Cancer Research and Treatment 137(2): 397-406.
• Bratton, M.R., B.N. Duong, S. Elliott, C.B. Weldon, B.S. Beckman, J.A. McLachlan, M.E. Burow. 2010. Regulation of ERα-mediated transcription of Bcl-2 by PI3K-AKT crosstalk: implications for breast cancer cell survival. International Journal of Oncology 37(3): 541-550.
• Bratton, M.R., D.E. Frigo, H.C. Segar, K.P. Nephew, J.A. McLachlan, T.E. Wiese, M.E. Burow. 2012. The organochlorine o,p'-DDT plays a role in coactivator-mediated MAPK crosstalk in MCF-7 breast cancer cells. Environmental Health Perspectives 120(9): 1291-1296.
• Brent, G.A. 2012. Mechanisms of thyroid hormone action. Journal of Clinical Investigation 122(9): 3035-3043.
• Brown, S.G., A.E. Knowell, A. Hunt, D. Patel, S. Bhosle, J. Chaudhary. 2015. Interferon inducible antiviral MxA is inversely associated with prostate cancer and regulates cell cycle, invasion and Docetaxel induced apoptosis. Prostate 75(3): 266-279.
• Caligiuri, I., G. Toffoli, A. Giordano, F. Rizzolio. 2013. pRb controls estrogen receptor α protein stability and activity. Oncotarget 4(6): 875-883.
• Castoria, G., P. Giovannelli, M. Di Donato, R. Hayashi, C. Arra, E. Appella, F. Auricchio, A. Migliaccio. 2013. Targeting androgen receptor/Src complex impairs the aggressive phenotype of human fibrosarcoma cells. PLoS One 8(10): e76899.
• Charles, G.D. 2004. In vitro models in endocrine disruptor screening. ILAR Journal 45(4): 494-501.
• Chen, M., M.A. Feuerstein, E. Levina, P.S. Baghel, R.D. Carkner, M.J. Tanner, M. Shtutman, F. Vacherot, S. Terry, A. de la Taille, R. Buttyan. 2010. Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells. Molecular Cancer 9: 89.
• Chen, W.J., Y.H. Yeh, K.H. Lin, G.J. Chang, C.T. Kuo. 2011. Molecular characterization of thyroid hormone-inhibited atrial L-type calcium channel expression: implication for atrial fibrillation in hyperthyroidism. Basic Research in Cardiology 106(2): 163-174.
• Cheng, S.Y., J.L. Leonard, P.J. Davis. 2010. Molecular aspects of thyroid hormone actions. Endocrine Reviews 31(2): 139-170.
• Cheskis, B.J., J. Greger, N. Cooch, C. McNally, S. Mclarney, H.S. Lam, S. Rutledge, B. Mekonnen, D. Hauze, S. Nagpal, L.P. Freedman. 2008. MNAR plays an important role in ERα activation of Src/MAPK and PI3K/Akt signaling pathways. Steroids 73(910): 901-905.
• Citro, S., C. Miccolo, L. Meloni, S. Chiocca. 2015. PI3K/mTOR mediate mitogen-dependent HDAC1 phosphorylation in breast cancer: a novel regulation of estrogen receptor expression. Journal of Molecular Cell Biology 7(2): 132-142.
• Cottu, P., I. Bi¯che, F. Assayag, R. El Botty, S. Chateau-Joubert, A. Thuleau, T. Bagarre, B. Albaud, A. Rapinat, D. Gentien, P. de la Grange, V. Sibut, S. Vacher, R. Hatem, J.L. Servely, J.J. Fontaine, D. Decaudin, J.Y. Pierga, S. Roman-Roman, E. Marangoni. 2014. Acquired resistance to endocrine treatments is associated with tumor-specific molecular changes in patient-derived luminal breast cancer xenografts. Clinical Cancer Research 20(16): 4314-4325.
• Culig, Z. 2004. Androgen receptor cross-talk with cell signalling pathways. Growth Factors 22(3): 179-184.
• Dahlman, K.B., J.S. Parker, T. Shamu, H. Hieronymus, C. Chapinski, B. Carver, K. Chang, G.J. Hannon, C.L. Sawyers. 2012. Modulators of prostate cancer cell proliferation and viability identified by shorthairpin RNA library screening. PLoS One 7(4): e34414.
• De Marco, P., V. Bartella, A. Vivacqua, R. Lappano, M.F. Santolla, A. Morcavallo, V. Pezzi, A. Belfiore, M. Maggiolini. 2013. Insulinlike growth factor-I regulates GPER expression and function in cancer cells. Oncogene 32(6): 678-688.
• Denison, M.S., A. Pandini, S.R. Nagy, E.P. Baldwin, L. Bonati. 2002. Ligand binding and activation of the Ah receptor. Chemico-Biological Interactions 141(1-2): 3-24.
• Di Donato, M., A. Bilancio, L. D'Amato, P. Claudiani, M.A. Oliviero, M.V. Barone, A. Auricchio, E. Appella, A. Migliaccio, F. Auricchio, G. Castoria. 2015. Cross-talk between androgen receptor/filamin A and TrkA regulates neurite outgrowth in PC12 cells. Molecular Biology of the Cell 26(15): 2858-2872.
• Dos Santos, E., M.N. Dieudonné, M.C. Leneveu, V. Sérazin, V. Rincheval, B. Mignotte, E. Chouillard, P. De Mazancourt, Y. Giudicelli, R. Pecquery. 2010. Effects of 17β-estradiol on preadipocyte proliferation in human adipose tissue: Involvement of IGF1-R signaling. Hormone and Metabolic Research 42(7): 514-520.
• Du, G., O. Shen, H. Sun, J. Fei, C. Lu, L. Song, Y. Xia, S. Wang, X. Wang. 2010. Assessing hormone receptor activities of pyrethroid insecticides and their metabolites in reporter gene assays. Toxicological Sciences 116(1): 58-66.
• Duarte-Guterman, P., V.L. Trudeau. 2010. Regulation of thyroid hormone-, oestrogen- and androgen-related genes by triiodothyronine in the brain of Silurana tropicalis. Journal of Neuroendocrinology 22(9): 1023-1031.
• Duarte-Guterman, P., L. Navarro-Martín, V.L. Trudeau. 2014. Mechanisms of crosstalk between endocrine systems: regulation of sex steroid hormone synthesis and action by thyroid hormones. General and Comparative Endocrinology 203: 69-85.
• Edwards, S.W., Y.M. Tan, D.L. Villeneuve, M.E. Meek, C.A. McQueen. 2016. Adverse outcome pathways-organizing toxicological information to improve decision making. Journal of Pharmacology and Experimental Therapeutics 356(1): 170-181.
• Ernst, J., J.C. Jann, R. Biemann, H.M. Koch, B. Fischer. 2014. Effects of the environmental contaminants DEHP and TCDD on estradiol synthesis and aryl hydrocarbon receptor and peroxisome proliferator-activated receptor signalling in the human granulosa cell line KGN. Molecular Human Reproduction 20(9): 919-928.
• Facompre, N.D., K. El-Bayoumy, Y.W. Sun, J.T. Pinto, R. Sinha. 2010. 1,4-phenylenebis(methylene)selenocyanate, but not selenomethionine, inhibits androgen receptor and Akt signaling in human prostate cancer cells. Cancer Prevention Research 3(8): 975-984.
• Fagan, D.H., D. Yee. 2008. Crosstalk between IGF1R and estrogen receptor signaling in breast cancer. Journal of Mammary Gland Biology and Neoplasia 13(4): 423-429.
• Fernandez, E.V., K.M. Reece, A.M. Ley, S.M. Troutman, T.M. Sissung, D.K. Price, C.H. Chau, W.D. Figg. 2015. Dual targeting of the androgen receptor and hypoxia-inducible factor 1α pathways synergistically inhibits castration-resistant prostate cancer cells. Molecular Pharmacology 87(6): 1006-1012.
• Fiorelli, A., C. Ricciardi, G. Pannone, A. Santoro, P. Bufo, M. Santini, R. Serpico, R. Rullo, G.M. Pierantoni, M. Di Domenico. 2011. Interplay between steroid receptors and neoplastic progression in sarcoma tumors. Journal of Cellular Physiology 226(11): 2997-3003.
• Fioretti, F.M., A. Sita-Lumsden, C.L. Bevan, G.N. Brooke. 2014. Revising the role of the androgen receptor in breast cancer. Journal of Molecular Endocrinology 52(3): R257-R265.
• FitzGerald, R.E., M.F. Wilks. 2014. Bisphenol A-Why an adverse outcome pathway framework needs to be applied. Toxicological Letters 230(2): 368-374.
• Fu, X., C.K. Osborne, R. Schiff. 2013. Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer. Breast 22 Suppl 2: S12-S18.
• Gao, Y., E. Huang, H. Zhang, J. Wang, N. Wu, X. Chen, N. Wang, S. Wen, G. Nan, F. Deng, Z. Liao, D. Wu, B. Zhang, J. Zhang, R.C. Haydon, H.H. Luu, L.L. Shi, T.C. He. 2013. Crosstalk between Wnt/β-catenin and estrogen receptor signaling synergistically promotes osteogenic differentiation of mesenchymal progenitor cells. PLoS One 8(12): e82436.
• Garay, J.P., B. Karakas, A.M. Abukhdeir, D.P. Cosgrove, J.P. Gustin, M.J. Higgins, H. Konishi, Y. Konishi, J. Lauring, M. Mohseni, G.M. Wang, D. Jelovac, A. Weeraratna, C.A. Sherman Baust, P.J. Morin, A. Toubaji, A. Meeker, A.M. De Marzo, G. Lewis, A. Subhawong, P. Argani, B.H. Park. 2012. The growth response to androgen receptor signaling in ERα-negative human breast cells is dependent on p21 and mediated by MAPK activation. Breast Cancer Research 14(1): R27.
• Garrido, P., J. Morán, A. Alonso, S. González, C. González. 2013. 17β-estradiol activates glucose uptake via GLUT4 translocation and PI3K/Akt signaling pathway in MCF-7 cells. Endocrinology 154(6): 1979-1989.
• Gauthier, K., C. Billon, M. Bissler, M. Beylot, J.M. Lobaccaro, J.M. Vanacker, J. Samarut. 2010. Thyroid hormone receptor β (TRβ) and liver X receptor (LXR) regulate carbohydrate-response element-binding protein (ChREBP) expression in a tissueselective manner. Journal of Biological Chemistry 285(36): 28156-28163.
• Georgi, B., N. Korzeniewski, B. Hadaschik, C. Grüllich, W. Roth, H. Sültmann, S. Pahernik, M. Hohenfellner, S. Duensing. 2014. Evolving therapeutic concepts in prostate cancer based on genome-wide analyses (review). International Journal of Oncology 45(4): 1337-1344.
• Ghisari, M., M. Long, A. Tabbo, E.C. Bonefeld-Jørgensen. 2015. Effects of currently used pesticides and their mixtures on the function of thyroid hormone and aryl hydrocarbon receptor in cell culture. Toxicology and Applied Pharmacology 284(3): 292-303.
• Gil-Ibáñez, P., J. Bernal, B. Morte. 2014. Thyroid hormone regulation of gene expression in primary cerebrocortical cells: role of thyroid hormone receptor subtypes and interactions with retinoic acid and glucocorticoids. PLoS One 9(3): e91692.
• Giordano, C., Y. Cui, I. Barone, S. Ando, M.A. Mancini, V. Berno, S.A. Fuqua. 2010. Growth factor-induced resistance to tamoxifen is associated with a mutation of estrogen receptor α and its phosphorylation at serine 305. Breast Cancer Research and Treatment 119(1): 71-85.
• Giuliano, M., M.V. Trivedi, R. Schiff. 2013. Bidirectional crosstalk between the estrogen receptor and human epidermal growth factor receptor 2 signaling pathways in breast cancer: molecular basis and clinical implications. Breast Care 8(4): 256-262.
• Goffin, V., D.T. Hoang, R.L. Bogorad, M.T. Nevalainen. 2011. Prolactin regulation of the prostate gland: a female player in a male game. Nature Reviews Urology 8(11): 597-607.
• Gori, I., C. Pellegrini, D. Staedler, R. Russell, C. Jan, G.O. Canny. 2011. Tumor necrosis factor-α activates estrogen signaling pathways in endometrial epithelial cells via estrogen receptor α. Molecular and Cellular Endocrinology 345(1-2): 27-37.
• Gupta, N., S. Grebhardt, D. Mayer. 2012. Janus kinase 2-a novel negative regulator of estrogen receptor α function. Cellular Signalling 24(1): 151-161.
• Härkönen, P.L., H.K. Väänänen. 2006. Monocyte-macrophage system as a target for estrogen and selective estrogen receptor modulators. Annals of the New York Academy of Sciences 1089: 218-227.
• Harnish, D.C. 2006. Estrogen receptor ligands in the control of pathogenic inflammation. Current Opinion in Investigational Drugs 7(11): 997-1001.
• Harvey, C.B., G.R. Williams. 2002. Mechanism of thyroid hormone action. Thyroid 12(6): 441-446.
• Heinlein, C.A., C. Chang. 2002. The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions. Molecular Endocrinology 16(10): 2181-2187.
• Hihi, A.K., L. Michalik, W. Wahli. 2002. PPARs: transcriptional effectors of fatty acids and their derivatives. Cellular and Molecular Life Sciences 59(5): 790-798.
• Hollmén, M., F. Roudnicky, S. Karaman, M. Detmar. 2015. Characterization of macrophage-cancer cell crosstalk in estrogen receptor positive and triplenegative breast cancer. Scientific Reports 5: 9188.
• Hou, X., M. Zhao, T. Wang, G. Zhang. 2014. Upregulation of estrogen receptor mediates migration, invasion and proliferation of endometrial carcinoma cells by regulating the PI3K/AKT/mTOR pathway. Oncology Reports 31(3): 1175-1182.
• Hsu, L.H., K.J. Liu, M.F. Tsai, C.R. Wu, A.C. Feng, N.M. Chu, S.H. Kao. 2015. Estrogen adversely affects the prognosis of patients with lung adenocarcinoma. Cancer Science 106(1): 51-59.
• Hu, W., H. Liu, H. Sun, O. Shen, X. Wang, M.H. Lam, J.P. Giesy, X. Zhang, H. Yu. 2011. Endocrine effects of methoxylated brominated diphenyl ethers in three in vitro models. Marine Pollution Bulletin 62(11): 2356-2361.
• Huang, Y.H., C.H. Liao, R.N. Chen, C.J. Liao, K.H. Lin. 2010. Human testicular orphan receptor 4 enhances thyroid hormone receptor signaling. Journal of Cellular Physiology 222(2): 347-356.
• Hwang, K.A., M.A. Park, N.H. Kang, B.R. Yi, S.H. Hyun, E.B. Jeung, K.C. Choi. 2013. Anticancer effect of genistein on BG-1 ovarian cancer growth induced by 17β-estradiol or bisphenol A via the suppression of the crosstalk between estrogen receptor α and insulin-like growth factor-1 receptor signaling pathways. Toxicology and Applied Pharmacology 272(3): 637-646.
• Iglesias-Gato, D., Y.C. Chuan, P. Wikström, S. Augsten, N. Jiang, Y. Niu, A. Seipel, D. Danneman, M. Vermeij, L. Fernandez-Perez, G. Jenster, L. Egevad, G. Norstedt, A. Flores-Morales. 2014. SOCS2 mediates the cross talk between androgen and growth hormone signaling in prostate cancer. Carcinogenesis 35(1): 24-33.
• Ishida, E., K. Hashimoto, S. Okada, T. Satoh, M. Yamada, M. Mori. 2013. Thyroid hormone receptor and liver X receptor competitively up-regulate human selective Alzheimer's disease indicator-1 gene expression at the transcriptional levels. Biochemical and Biophysical Research Communications 432(3): 513-518.
• Itkonen, H.M., I.G. Mills. 2013. N-linked glycosylation supports cross-talk between receptor tyrosine kinases and androgen receptor. PLoS One 8(5): e65016.
• Ito, T., S. Kamijo, H. Izumi, K. Kohno, J. Amano, K. Ito. 2012. Alteration of Y-box binding protein-1 expression modifies the response to endocrine therapy in estrogen receptor-positive breast cancer. Breast Cancer Research and Treatment 133(1): 145-159.
• Izumi, K., Y. Zheng, Y. Li, J. Zaengle, H. Miyamoto. 2012. Epidermal growth factor induces bladder cancer cell proliferation through activation of the androgen receptor. International Journal of Oncology 41(5): 1587-1592.
• Jiang, Q.F., T.T. Wu, J.Y. Yang, C.R. Dong, N. Wang, X.H. Liu, Z.M. Liu. 2013. 17β-estradiol promotes the invasion and migration of nuclear estrogen receptor-negative breast cancer cells through cross-talk between GPER1 and CXCR1. Journal of Steroid Biochemistry and Molecular Biology 138: 314-324.
• Jin, K., X. Kong, T. Shah, M.F. Penet, F. Wildes, D.C. Sgroi, X.J. Ma, Y. Huang, A. Kallioniemi, G. Landberg, I. Bieche, X. Wu, P.E. Lobie, N.E. Davidson, Z.M. Bhujwalla, T. Zhu, S. Sukumar. 2012. The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway. Proceedings of the National Academy of Sciences of the United States of America 109(8): 2736-2741.
• Johnston, S.R. 2006. Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in breast cancer. Clinical Cancer Research 12(3 Pt 2): 1061s-1068s.
• Jung, H.H., Y.H. Park, H.J. Jun, J. Kong, J.H. Kim, J.A. Kim, J. Yun, J.M. Sun, Y.W. Won, S. Lee, S.T. Kim, J.S. Ahn, Y.H. Im. 2010. Matrix metalloproteinase-1 expression can be upregulated through mitogen-activated protein kinase pathway under the influence of human epidermal growth factor receptor 2 synergized with estrogen receptor. Molecular Cancer Research 8(7): 1037-1047.
• Kaarbø, M., O.L. Mikkelsen, L. Malerød, S. Qu, V.H. Lobert, G. Akgul, T. Halvorsen, G.M. Maelandsmo, F. Saatcioglu. 2010. PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells. Cellular Oncology 32(1-2): 11-27.
• Kang, N.H., K.A. Hwang, H.R. Lee, D.W. Choi, K.C. Choi. 2013. Resveratrol regulates the cell viability promoted by 17β-estradiol or bisphenol A via down-regulation of the cross-talk between estrogen receptor α and insulin growth factor-1 receptor in BG-1 ovarian cancer cells. Food and Chemical Toxicology 59: 373-379.
• Kastrati, I., E. Canestrari, J. Frasor. 2015. PHLDA1 expression is controlled by an estrogen receptor-NFκB-miR-181 regulatory loop and is essential for formation of ER+ mammospheres. Oncogene 34(18): 2309-2316.
• Kato, M., H. Takaishi, M. Yoda, T. Tohmonda, J. Takito, N. Fujita, N. Hosogane, K. Horiuchi, T. Kimura, Y. Okada, T. Saito, H. Kawaguchi, T. Kikuchi, M. Matsumoto, Y. Toyama, K. Chiba. 2010. GRIP1 enhances estrogen receptor α-dependent extracellular matrix gene expression in chondrogenic cells. Osteoarthritis and Cartilage 18(7): 934-941.
• Katzenellenbogen, B.S. 2000. Mechanisms of action and cross-talk between estrogen receptor and progesterone receptor pathways. Journal of the Society for Gynecologic Investigation 7(1 Suppl): S33-S37.
• Kavlock, R.J., G.P. Daston, C. DeRosa, P. Fenner-Crisp, L.E. Gray, S. Kaattari, G. Lucier, M. Luster, M.J. Mac, C. Maczka, R. Miller, J. Moore, R. Rolland, G. Scott, D.M. Sheehan, T. Sinks, H.A. Tilson. 1996. Research needs for the risk assessment of health and environmental effects of endocrine disruptors: a report of the U.S. EPA-sponsored workshop. Environmental Health Perspectives 104 Suppl 4: 715-740.
• Kawano, M., X.Y. Qin, M. Yoshida, T. Fukuda, H. Nansai, Y. Hayashi, T. Nakajima, H. Sone. 2014. Peroxisome proliferatoractivated receptor α mediates di-(2-ethylhexyl) phthalate transgenerational repression of ovarian Esr1 expression in female mice. Toxicology Letters 228(3): 235-240.
• Khetan, S.K. 2014. Endocrine Disruptors in the Environment. 408 p. Wiley, Hoboken, New Jersey.
• Kiyama, R., Y. Wada-Kiyama. 2015. Estrogenic endocrine disruptors: Molecular mechanisms of action. Environment International 83: 11-40.
• Kiyama, R., Y. Zhu, K. Kawaguchi, N. Iitake, Y. Wada-Kiyama, S. Dong. 2014. Estrogen-responsive genes for environmental studies. Environmental Technology and Innovation 1-2: 16-28.
• Knapen, D., L. Vergauwen, D.L. Villeneuve, G.T. Ankley. 2015. The potential of AOP networks for reproductive and developmental toxicity assay development. Reproductive Toxicology 56: 52-55.
• Koochekpour, S. 2010. Androgen receptor signaling and mutations in prostate cancer. Asian Journal of Andrology 12(5): 639-657.
• Kouidhi, S., I. Seugnet, S. Decherf, H. Guissouma, A.B. Elgaaied, B. Demeneix, M.S. Clerget-Froidevaux. 2010. Peroxisome proliferatoractivated receptor-γ (PPARγ) modulates hypothalamic Trh regulation in vivo. Molecular and Cellular Endocrinology 317 (1-2): 44-52.
• Krycer, J.R., A.J. Brown. 2011. Cross-talk between the androgen receptor and the liver X receptor: implications for cholesterol homeostasis. Journal of Biological Chemistry 286(23): 20637-20647.
• Krycer, J.R., A.J. Brown. 2013. Does changing androgen receptor status during prostate cancer development impact upon cholesterol homeostasis? PLoS One 8(1): e54007.
• Kumar, S., B. Jaiswal, S. Kumar, S. Negi, R.K. Tyagi. 2010. Cross-talk between androgen receptor and pregnane and xenobiotic receptor reveals existence of a novel modulatory action of antiandrogenic drugs. Biochemical Pharmacology 80(7): 964-976.
• Langlois, V.S., P. Duarte-Guterman, V.L. Trudeau. 2011. Expression profiles of reproduction- and thyroid hormone-related transcripts in the brains of chemically-induced intersex frogs. Sexual Development 5(1): 26-32.
• Lanzino, M., C. Morelli, C. Garofalo, M.L. Panno, L. Mauro, S. Andò, D. Sisci. 2008. Interaction between estrogen receptor α and insulin/IGF signaling in breast cancer. Current Cancer Drug Targets 8(7): 597-610.
• Lawrence, M.G., N.V. Margaryan, D. Loessner, A. Collins, K.M. Kerr, M. Turner, E.A. Seftor, C.R. Stephens, J. Lai; APC BioResource, L.M. Postovit, J.A. Clements, M.J. Hendrix. 2011. Reactivation of embryonic nodal signaling is associated with tumor progression and promotes the growth of prostate cancer cells. Prostate 71(11): 1198-1209.
• Le, T.Y., A.W. Ashton, M. Mardini, P.G. Stanton, J.W. Funder, D.J. Handelsman, A.S. Mihailidou. 2014. Role of androgens in sex differences in cardiac damage during myocardial infarction. Endocrinology 155(2): 568-575.
• Leary, A.F., S. Drury, S. Detre, S. Pancholi, A.E. Lykkesfeldt, L.A. Martin, M. Dowsett, S.R. Johnston. 2010. Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance. Clinical Cancer Research 16(5): 1486-1497.
• Lee, H.R., K.A. Hwang, K.C. Choi. 2014. The estrogen receptor signaling pathway activated by phthalates is linked with transforming growth factor-β in the progression of LNCaP prostate cancer models. International Journal of Oncology 45(2): 595-602.
• Lee, J.S., E.Y. Kim, K. Nomaru, H. Iwata. 2011. Molecular and functional characterization of Aryl hydrocarbon receptor repressor from the chicken (Gallus gallus): interspecies similarities and differences. Toxicological Sciences 119(2): 319-334.
• Li, Y., Y. Zheng, K. Izumi, H. Ishiguro, B. Ye, F. Li, H. Miyamoto. 2013. Androgen activates β-catenin signaling in bladder cancer cells. Endocrine-Related Cancer 20(3): 293-304.
• Lim, S.K., M. Orhant-Prioux, W. Toy, K.Y. Tan, Y.P. Lim. 2011. Tyrosine phosphorylation of transcriptional coactivator WWdomain binding protein 2 regulates estrogen receptor α function in breast cancer via the Wnt pathway. FASEB Journal 25(9): 3004-3018.
• Liu, Q., Y. Wang, J. Gu, Y. Yuan, X. Liu, W. Zheng, Q. Huang, Z. Liu, J. Bian. 2014a. Zearalenone inhibits testosterone biosynthesis in mouse Leydig cells via the crosstalk of estrogen receptor signaling and orphan nuclear receptor Nur77 expression. Toxicology In Vitro 28(4): 647-656.
• Liu, W., J. Zhou, G. Geng, R. Lin, J.H. Wu. 2014b. Synthesis and in vitro characterization of ionone-based compounds as dual inhibitors of the androgen receptor and NF-κB. Investigational New Drugs 32(2): 227-234.
• Liu, Y.Y., G.A. Brent. 2010. Thyroid hormone crosstalk with nuclear receptor signaling in metabolic regulation. Trends in Endocrinology and Metabolism 21(3): 166-173.
• Lu, T., W.J. Lin, K. Izumi, X. Wang, D. Xu, L.Y. Fang, L. Li, Q. Jiang, J. Jin, C. Chang. 2012. Targeting androgen receptor to suppress macrophage-induced EMT and benign prostatic hyperplasia (BPH) development. Molecular Endocrinology 26(10): 1707-1715.
• Luccio-Camelo, D.C., G.S. Prins. 2011. Disruption of androgen receptor signaling in males by environmental chemicals. Journal of Steroid Biochemistry and Molecular Biology 127(1-2): 74-82.
• Mandal, A., D. Bhatia, A. Bishayee. 2013. Simultaneous disruption of estrogen receptor and Wnt/β-catenin signaling is involved in methyl amooranin-mediated chemoprevention of mammary gland carcinogenesis in rats. Molecular and Cellular Biochemistry 384(1-2): 239-250.
• Manolio, T.A. 2010. Genomewide association studies and assessment of the risk of disease. New England Journal of Medicine 363(2): 166-176.
• Marques, R.B., A. Aghai, C.M. de Ridder, D. Stuurman, S. Hoeben, A. Boer, R.P. Ellston, S.T. Barry, B.R. Davies, J. Trapman, W.M. van Weerden. 2015. High efficacy of combination therapy using PI3K/AKT inhibitors with androgen deprivation in prostate cancer preclinical models. European Urology 67(6): 1177-1185.
• Massarweh, S., R. Schiff. 2006. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk. Endocrine-Related Cancer 13 Suppl 1: S15-S24.
• Mellado, B., J. Codony, M.J. Ribal, L. Visa, P. Gascón. 2009. Molecular biology of androgen-independent prostate cancer: the role of the androgen receptor pathway. Clinical and Translational Oncology 11(1): 5-10.
• Mellado, B., M. Marin Aguilera, M.V. Pereira. 2013. Molecular biology of castration-resistant prostate cancer: basis for the novel therapeutic targets. Archivos Españoles de Urología 66(5): 453-462.
• Meulenbeld, H.J., J.S. de Bono, S.T. Tagawa, Y.E. Whang, X. Li, K.H. Heath, A.S. Zandvliet, S.W. Ebbinghaus, G.R. Hudes, R. de Wit. 2013. Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC). Cancer Chemotherapy and Pharmacology 72(4): 909-916.
• Michels, G., U.C. Hoppe. 2008. Rapid actions of androgens. Frontiers in Neuroendocrinology 29(2): 182-198.
• Mooradian, A.D., J.E. Morley, S.G. Korenman. 1987. Biological actions of androgens. Endocrine Reviews 8(1): 1-28.
• Mordan-McCombs, S., T. Brown, W.L. Wang, A.C. Gaupel, J. Welsh, M. Tenniswood. 2010. Tumor progression in the LPB-Tag transgenic model of prostate cancer is altered by vitamin D receptor and serum testosterone status. Journal of Steroid Biochemistry and Molecular Biology 121(1-2): 368-371.
• Morelli, C., M. Lanzino, C. Garofalo, P. Maris, E. Brunelli, I. Casaburi, S. Catalano, R. Bruno, D. Sisci, S. Andò. 2010. Akt2 inhibition enables the forkhead transcription factor FoxO3a to have a repressive role in estrogen receptor α transcriptional activity in breast cancer cells. Molecular and Cellular Biology 30(3): 857-870.
• Mulholland, D.J., L.M. Tran, Y. Li, H. Cai, A. Morim, S. Wang, S. Plaisier, I.P. Garraway, J. Huang, T.G. Graeber, H. Wu. 2011. Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell 19(6): 792-804.
• Mullur, R., Y.Y. Liu, G.A. Brent. 2014. Thyroid hormone regulation of metabolism. Physiological Reviews 94(2): 355-382.
• Muth-Köhne, E., K. Westphal-Settele, J. Brückner, S. Konradi, V. Schiller, C. Schäfers, M. Teigeler, M. Fenske. 2016. Linking the response of endocrine regulated genes to adverse effects on sex differentiation improves comprehension of aromatase inhibition in a Fish Sexual Development Test. Aquatic Toxicology 176: 116-127.
• Naderi, A., J. Liu. 2010. Inhibition of androgen receptor and Cdc25A phosphatase as a combination targeted therapy in molecular apocrine breast cancer. Cancer Letters 298(1): 74-87.
• Nahta, R., R.M. O'Regan. 2012. Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers. Breast Cancer Research and Treatment 135(1): 39-48.
• Nair, B.C., S. Vallabhaneni, R.R. Tekmal, R.K. Vadlamudi. 2011. Roscovitine confers tumor suppressive effect on therapy-resistant breast tumor cells. Breast Cancer Research 13(3): R80.
• National Research Council. 2007. Toxicity Testing in the 21st Century: A Vision and a Strategy. 216 p. Washington, D.C., National Academies Press.
• Need, E.F., L.A. Selth, T.J. Harris, S.N. Birrell, W.D. Tilley, G. Buchanan. 2012. Research resource: interplay between the genomic and transcriptional networks of androgen receptor and estrogen receptor α in luminal breast cancer cells. Molecular Endocrinology 26(11): 1941-1952.
• Osborne, C.K., R. Schiff. 2011. Mechanisms of endocrine resistance in breast cancer. Annual Review of Medicine 62: 233-247.
• Osborne, C.K., J. Shou, S. Massarweh, R. Schiff. 2005. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clinical Cancer Research 11(2 Pt 2): 865s-870s.
• Park, M.A., K.C. Choi. 2014. Effects of 4-nonylphenol and bisphenol A on stimulation of cell growth via disruption of the transforming growth factor-β signaling pathway in ovarian cancer models. Chemical Research in Toxicology 27(1): 119-128.
• Paul, K.B., J.T. Thompson, S.O. Simmons, J.P. Vanden Heuvel, K.M. Crofton. 2013. Evidence for triclosan-induced activation of human and rodent xenobiotic nuclear receptors. Toxicology In Vitro 27(7): 2049-2060.
• Rajendran, M., P. Thomes, L. Zhang, S. Veeramani, M.F. Lin. 2010. p66Shc-a longevity redox protein in human prostate cancer progression and metastasis : p66Shc in cancer progression and metastasis. Cancer Metastasis Reviews 29(1): 207-222.
• Rataj, F., F.J. Möller, M. Jähne, O. Zierau, P. Diel, G. Vollmer, G. Kretzschmar. 2012. Regulation of uterine AHR battery gene expression by 17β-estradiol is predominantly mediated by estrogen receptor α. Archives of Toxicology 86(10): 1603-1612.
• Riverso, M., A. Kortenkamp, E. Silva. 2014. Non-tumorigenic epithelial cells secrete MCP-1 and other cytokines that promote cell division in breast cancer cells by activating ERα via PI3K/Akt/mTOR signaling. International Journal of Biochemistry and Cell Biology 53: 281-294.
• Rocha, J., F.Z. Zouanat, A. Zoubeidi, L. Hamel, T. Benidir, E. Scarlata, F. Brimo, A. Aprikian, S. Chevalier. 2013. The Fer tyrosine kinase acts as a downstream interleukin-6 effector of androgen receptor activation in prostate cancer. Molecular and Cellular Endocrinology 381(1-2): 140-149.
• Roy, A.K., Y. Lavrovsky, C.S. Song, S. Chen, M.H. Jung, N.K. Velu, B.Y. Bi, B. Chatterjee. 1999. Regulation of androgen action. Vitamins and Hormones 55: 309-352.
• Ruan, S.Q., Z.H. Wang, S.W. Wang, Z.X. Fu, K.L. Xu, D.B. Li, S.Z. Zhang. 2012. Heregulin-β1-induced GPR30 upregulation promotes the migration and invasion potential of SkBr3 breast cancer cells via ErbB2/ErbB3-MAPK/ERK pathway. Biochemical and Biophysical Research Communications 420(2): 385-390.
• Safe, S.H. 2000. Endocrine disruptors and human Heath-is there a problem? An update. Environmental Health Perspectives 108(6): 487-493.
• Safe, S., F. Wang, W. Porter, R. Duan, A. McDougal. 1998. Ah receptor agonists as endocrine disruptors: antiestrogenic activity and mechanisms. Toxicology Letters 102-103: 343-347.
• Safe, S., M. Wormke. 2003. Inhibitory aryl hydrocarbon receptorestrogen receptor α cross-talk and mechanisms of action. Chemical Research in Toxicology 16(7): 807-816.
• Santolla, M.F., R. Lappano, P. De Marco, M. Pupo, A. Vivacqua, D. Sisci, S. Abonante, D. Iacopetta, A.R. Cappello, V. Dolce, M. Maggiolini. 2012. G protein-coupled estrogen receptor mediates the up-regulation of fatty acid synthase induced by 17β-estradiol in cancer cells and cancer-associated fibroblasts. Journal of Biological Chemistry 287(52): 43234-43245.
• Sayeed, A., N. Alam, M. Trerotola, L.R. Languino. 2012. Insulin-like growth factor 1 stimulation of androgen receptor activity requires β(1A) integrins. Journal of Cellular Physiology 227(2): 751-758.
• Schayowitz, A., G. Sabnis, O. Goloubeva, V.C. Njar, A.M. Brodie. 2010. Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR. British Journal of Cancer 103(7): 1001-1007.
• Schiff, R., S.A. Massarweh, J. Shou, L. Bharwani, G. Arpino, M. Rimawi, C.K. Osborne. 2005. Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemotherapy and Pharmacology 56 Suppl 1: 10-20.
• Scholz, S., P. Renner, S.E. Belanger, F. Busquet, R. Davi, B.A. Demeneix, J.S. Denny, M. Léonard, M.E. McMaster, D.L. Villeneuve, M.R. Embry. 2013. Alternatives to in vivo tests to detect endocrine disrupting chemicals (EDCs) in fish and amphibians-screening for estrogen, androgen and thyroid hormone disruption. Critical Reviews in Toxicology 43(1): 45-72.
• Schug, T.T., S.A. Vogel, L.N. Vandenberg, J.M. Braun, R. Hauser, J.A. Taylor, F.S. vom Saal, J.J. Heindel. 2012. Bisphenol A. In: Dioxins and Health (ed. A. Schecter), pp. 381-413. John Wiley & Sons.
• Shen, H., Y. Yuan, J. Sun, W. Gao, Y.Q. Shu. 2010. Combined tamoxifen and gefitinib in non-small cell lung cancer shows antiproliferative effects. Biomedicine and Pharmacotherapy 64(2): 88-92.
• Silva, E., A. Kabil, A. Kortenkamp. 2010. Cross-talk between nongenomic and genomic signalling pathways-distinct effect profiles of environmental estrogens. Toxicology and Applied Pharmacology 245(2): 160-170.
• Smith, C.L. 1998. Cross-talk between peptide growth factor and estrogen receptor signaling pathways. Biology of Reproduction 58(3): 627-632.
• Song, C.H., H.J. Lee, E. Park, K. Lee. 2012. The chicken ovalbumin upstream promoter-transcription factor II negatively regulates the transactivation of androgen receptor in prostate cancer cells. PLoS One 7(11): e49026.
• Spanheimer, P.M., A.R. Cyr, M.P. Gillum, G.W. Woodfield, R.W. Askeland, R.J. Weigel. 2014. Distinct pathways regulated by RET and estrogen receptor in luminal breast cancer demonstrate the biological basis for combination therapy. Annals of Surgery 259(4): 793-799.
• Squillace, R.M., D. Miller, S.D. Wardwell, F. Wang, T. Clackson, V.M. Rivera. 2012. Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models. International Journal of Oncology 41(2): 425-432.
• Stabile, L.P., J.M. Siegfried. 2004. Estrogen receptor pathways in lung cancer. Current Oncology Reports 6(4): 259-267.
• Stein, R.A., D.P. McDonnell. 2006. Estrogen-related receptor α as a therapeutic target in cancer. Endocrine-Related Cancer 13 Suppl 1: S25-S32.
• Stope, M.B., S.L. Popp, C. Knabbe, M.B. Buck. 2010. Estrogen receptor α attenuates transforming growth factor-β signaling in breast cancer cells independent from agonistic and antagonistic ligands. Breast Cancer Research and Treatment 120(2): 357-367.
• Su, F., B.R. Correa, J. Luo, R.Z. Vencio, L.E. Pascal, Z. Wang. 2013. Gene expression profiling reveals regulation of ERK phosphorylation by androgen-induced tumor suppressor U19/EAF2 in the mouse prostate. Cancer Microenvironment 6(3): 247-261.
• Sun, H., C. Si, Q. Bian, X. Chen, L. Chen, X. Wang. 2012. Developing in vitro reporter gene assays to assess the hormone receptor activities of chemicals frequently detected in drinking water. Journal of Applied Toxicology 32(8): 635-641.
• Surmacz, E., M. Bartucci. 2004. Role of estrogen receptor α in modulating IGF-I receptor signaling and function in breast cancer. Journal of Experimental and Clinical Cancer Research 23(3): 385-394.
• Tabb, M.M., B. Blumberg. 2006. New modes of action for endocrinedisrupting chemicals. Molecular Endocrinology 20(3): 475-482.
• Takada, M., T. Higuchi, K. Tozuka, H. Takei, M. Haruta, J. Watanabe, F. Kasai, K. Inoue, M. Kurosumi, M. Miyazaki, A. Sato-Otsubo, S. Ogawa, Y. Kaneko. 2013. Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy. BMC Cancer 13: 241.
• Tan, W.S., D.F. Carlson, M.W. Walton, S.C. Fahrenkrug, P.B. Hackett. 2012. Precision editing of large animal genomes. Advances in Genetics 80: 37-97.
• Thakkar, J.P., D.G. Mehta. 2011. A review of an unfavorable subset of breast cancer: estrogen receptor positive progesterone receptor negative. Oncologist 16(3): 276-285.
• Thorne, C., A.V. Lee. 2003. Cross talk between estrogen receptor and IGF signaling in normal mammary gland development and breast cancer. Breast Disease 17: 105-114.
• Toraldo, G., S. Bhasin, M. Bakhit, W. Guo, C. Serra, J.D. Safer, J. Bhawan, R. Jasuja. 2012. Topical androgen antagonism promotes cutaneous wound healing without systemic androgen deprivation by blocking β catenin nuclear translocation and cross-talk with TGF-β signaling in keratinocytes. Wound Repair and Regeneration 20(1): 61-73.
• Totta, P., V. Pesiri, M. Marino, F. Acconcia. 2014. Lysosomal function is involved in 17β-estradiol-induced estrogen receptor α degradation and cell proliferation. PLoS One 9(4): e94880.
• Tovar, C., B. Higgins, K. Kolinsky, M. Xia, K. Packman, D.C. Heimbrook, L.T. Vassilev. 2011. MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer. Molecular Cancer 10: 49.
• Tsonis, A.I., N. Afratis, C. Gialeli, M.I. Ellina, Z. Piperigkou, S.S. Skandalis, A.D. Theocharis, G.N. Tzanakakis, N.K. Karamanos. 2013. Evaluation of the coordinated actions of estrogen receptors with epidermal growth factor receptor and insulin-like growth factor receptor in the expression of cell surface heparan sulfate proteoglycans and cell motility in breast cancer cells. FEBS Journal 280(10): 2248-2259.
• Valle, A., J. Sastre-Serra, J. Oliver, P. Roca. 2011. Chronic leptin treatment sensitizes MCF-7 breast cancer cells to estrogen. Cellular Physiology and Biochemistry 28(5): 823-832.
• Vandenberg, L.N., M.V. Maffini, C. Sonnenschein, B.S. Rubin, A.M. Soto. 2009. Bisphenol-A and the great divide: a review of controversies in the field of endocrine disruption. Endocrine Reviews 30(1): 75-95.
• Verras, M., Z. Sun. 2006. Roles and regulation of Wnt signaling and β-catenin in prostate cancer. Cancer Letters 237(1): 22-32.
• Villaronga, M.A., C.L. Bevan, B. Belandia. 2008. Notch signaling: a potential therapeutic target in prostate cancer. Current Cancer Drug Targets 8(7): 566-580.
• Wang, C., Y. Liu, J.M. Cao. 2014. G protein-coupled receptors: extranuclear mediators for the non-genomic actions of steroids. International Journal of Molecular Sciences 15(9): 15412-15425.
• Wang, S.J., X.F. Li, L.S. Jiang, L.Y. Dai. 2012a. Leptin regulates estrogen receptor gene expression in ATDC5 cells through the extracellular signal regulated kinase signaling pathway. Journal of Cellular Biochemistry 113(4): 1323-1332.
• Wang, Y.X., J.X. Gao, X.Y. Wang, L. Zhang, C.M. Liu. 2012b. Antiproliferative effects of selective cyclooxygenase-2 inhibitor modulated by nimotuzumab in estrogen-dependent breast cancer cells. Tumour Biology 33(4): 957-966.
• Wang, Y., J.I. Kreisberg, P.M. Ghosh. 2007. Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer. Current Cancer Drug Targets 7(6): 591-604.
• Wang, Y., X.L. Niu, X.Q. Guo, J. Yang, L. Li, Y. Qu, C. Xiu Hu, L.Q. Mao, D. Wang. 2015. IL6 induces TAM resistance via kinasespecific phosphorylation of ERα in OVCA cells. Journal of Molecular Endocrinology 54(3): 351-361.
• Wang, Y., T. Romigh, X. He, M.H. Tan, M.S. Orloff, R.H. Silverman, W.D. Heston, C. Eng. 2011. Differential regulation of PTEN expression by androgen receptor in prostate and breast cancers. Oncogene 30(42): 4327-4338.
• Wang, Z.Y., L. Yin. 2015. Estrogen receptor alpha-36 (ER-α36): A new player in human breast cancer. Molecular and Cellular Endocrinology 418 (Pt 3): 193-206.
• Wu, Y., R.R. Chhipa, J. Cheng, H. Zhang, J.L. Mohler, C. Ip. 2010. Androgen receptor-mTOR crosstalk is regulated by testosterone availability: implication for prostate cancer cell survival. Anticancer Research 30(10): 3895-3901.
• Xu, Y., N.Z. Zhang, J. Chen, H.Q. Yuan. 2013. Biomarkers in urothelial carcinoma of the bladder: the potential cross-talk between transforming growth factor-β1 and estrogen receptor β/androgen receptor pathways. Medical Hypotheses 80(6): 716-718.
• Yan, C., H. Wei, Z. Minjuan, X. Yan, Y. Jingyue, L. Wenchao, H. Sheng. 2014. The mTOR inhibitor rapamycin synergizes with a fatty acid synthase inhibitor to induce cytotoxicity in ER/HER2-positive breast cancer cells. PLoS One 9(5): e97697.
• Yang, L., P. Ravindranathan, M. Ramanan, P. Kapur, S.R. Hammes, J.T. Hsieh, G.V. Raj. 2012. Central role for PELP1 in nonandrogenic activation of the androgen receptor in prostate cancer. Molecular Endocrinology 26(4): 550-561.
• Yen, P.M. 2001. Physiological and molecular basis of thyroid hormone action. Physiological Reviews 81(3): 1097-1142.
• Zhang, D., V.L. Trudeau. 2006. Integration of membrane and nuclear estrogen receptor signaling. Comparative Biochemistry and Physiology Part A 144(3): 306-315.
• Zhang, F., F. Feng, P. Yang, Z. Li, J. You, W. Xie, X. Gao, J. Yang. 2012. Four-and-a-half-LIM protein 1 down-regulates estrogen receptor α activity through repression of AKT phosphorylation in human breast cancer cell. International Journal of Biochemistry and Cell Biology 44(2): 320-326.
• Zhang, K.X., J. Firus, B. Prieur, W. Jia, P.S. Rennie. 2011. To die or to survive, a fatal question for the destiny of prostate cancer cells after androgen deprivation therapy. Cancers 3(2): 1498-1512.
• Zhao, C., H. Gao, Y. Liu, Z. Papoutsi, S. Jaffrey, J.A. Gustafsson, K. Dahlman-Wright. 2010. Genome-wide mapping of estrogen receptor-β-binding regions reveals extensive cross-talk with transcription factor activator protein-1. Cancer Research 70(12): 5174-5183.
• Zheng, Y., K. Izumi, J.L. Yao, H. Miyamoto. 2011. Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptorpositive bladder cancer cells. Endocrine-Related Cancer 18(4): 451-464.
• Zhou, H., K. Mazan-Mamczarz, J.L. Martindale, A. Barker, Z. Liu, M. Gorospe, P.J. Leedman, R.B. Gartenhaus, A.W. Hamburger, Y. Zhang. 2010. Post-transcriptional regulation of androgen receptor mRNA by an ErbB3 binding protein 1 in prostate cancer. Nucleic Acids Research 38(11): 3619-3631.
• Zhou, Y., S. Eppenberger-Castori, U. Eppenberger, C.C. Benz. 2005. The NFκB pathway and endocrine-resistant breast cancer. Endocrine-Related Cancer 12 Suppl 1: S37-S46.
• Zhu, B., N. Kyprianou. 2005. Transforming growth factor β and prostate cancer. Prostate Cancer 126: 157-173.
• Zhuo, M., C. Zhu, J. Sun, W.I. Weis, Z. Sun. 2011. The β-catenin binding protein ICAT modulates androgen receptor activity. Molecular Endocrinology 25(10): 1677-1688.
• Zoeller, R.T., T.R. Brown, L.L. Doan, A.C. Gore, N.E. Skakkebaek, A.M. Soto, T.J. Woodruff, F.S. Vom Saal. 2012. Endocrinedisrupting chemicals and public health protection: a statement of principles from The Endocrine Society. Endocrinology 153(9): 4097-4110.